MedWatch

Veloxis expands to China and Canada

The Danish pharmaceutical company Veloxis has entered more new agreements to market its main product Envarsus XR in both Canada and China.

Foto: Colourbox

Pentecost has been busy for Veloxis Pharmaceuticals, which has entered two new license agreements for the Canadian as well as the Chinese and Taiwanese markets.

In Canada, the drug company Paladin Labs takes over the rights to Veloxis’ drug Envarsus XR, which is used for preventing organ rejection in kidney transplant patients.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier